132 related articles for article (PubMed ID: 37368100)
1. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
[TBL] [Abstract][Full Text] [Related]
2. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract][Full Text] [Related]
4. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ
Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Falchook GS; Sachdev J; Imedio ER; Kumar S; Mugundu GM; Jenkins S; Chmielecki J; Jones S; Spigel DR; Johnson M
Invest New Drugs; 2023 Jun; 41(3):493-502. PubMed ID: 37171722
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
[TBL] [Abstract][Full Text] [Related]
8. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
[TBL] [Abstract][Full Text] [Related]
9. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
10. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
[TBL] [Abstract][Full Text] [Related]
11. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
Kuchimanchi M; Dabrowski C; Lu S; Melhem M
Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of WEE1 Is Effective in
Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
[TBL] [Abstract][Full Text] [Related]
13. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
14. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
[TBL] [Abstract][Full Text] [Related]
15. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
[TBL] [Abstract][Full Text] [Related]
16. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
[TBL] [Abstract][Full Text] [Related]
17. Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
Mendzelevski B; Ferber G; Janku F; Li BT; Sullivan RJ; Welsch D; Chi W; Jackson J; Weng O; Sager PT
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1129-1141. PubMed ID: 29603015
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S
Int J Gynecol Cancer; 2023 Aug; 33(8):1208-1214. PubMed ID: 37380217
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
